Image

Lupus Nephritis

Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.

 

Know more with
AVISE® SLE Monitor

The most advanced assessment available

With a powerful combination of biomarkers that go beyond standard SLE tests, AVISE® SLE Monitor empowers you with the full intel to stay a step ahead of flare ups, regularly monitor disease progression, assess treatment efficacy, and help prevent premature disease advancement and long-term damage.

Image

A more advanced assessment requires a more comprehensive biomarker suite


AVISE SLE Monitor

Organ involvement

PC4d Powered by CB-CAPs
Anti-C1q

Disease Activity

Soluble C3/C4
Anti-dsDNA by CIA
EC4d Powered by CB-CAPs

Optional Add-Ons

Therapeutic drug monitoring

HCQ
MTX

EC4d is informative even when C3/C4 is unchanged

In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.5

22%

Fluctuating C3/C4 Levels

78% EC4d disease correlation independent of C3/C4 levels in this patient group

Chronic Levels

Marginal R2 =7.9% (p <0.001)

ES4d is informative even when C3/C4 is unchanged

In a cohort of 124 SLE patients that were followed longitudinally, levels of EC4d fluctuated with disease activity and provided additional information regardless of changes in C3/C4 levels.

22%

Fluctuating C3/C4 Levels

78% EC4d disease correlation independent of C3/C4 levels in this patient group

Chronic Low or Normal C3/C4 Levels

Marginal R2 =7.9% (p <0.001)

Image

Superior detection of organ involvement


PC4d: Detect the potential for thrombosis

Our patented CB-CAPs PC4d test has a strong association with a history of thrombosis and risk for ischemic stroke independent of antiphospholipid antibody levels.

Percent of SLE patients with Thrombosis by PC4d status2

30%

PC4d positive

5%

PC4d negative

Anti-C1q: Identify the risk of Lupus Nephritis

Anti-C1q is superior to other biomarkers in association with SELENA-SLEDAI values and lupus nephritis. SLE patients with positive levels are 2X more likely to have renal involvement.

Percent of patients with increased biomarker levels during high disease activity4

35-44% C3/C4
50% Anti-dsDNA
63% Anti-C1q


Superior detection of changes in disease activity


EC4d: More accurate monitoring

Our proprietary CB-CAPs EC4d test has strong correlation with disease activity and levels decline rapidly with clinical improvement.5


Anti-dsDNA by CIA: Superior accuracy

Chemiluminescence immunoassay (CIA) has expanded dynamic range and demonstrated superior agreement with the Farr assay.1


Superior detection of Lupus Nephritis


EC4d and anti-C1q significantly correlate with decreases in proteinuria observed prospectively—importantly, EC4d had a stronger correlation with uPCR than conventional serum C3/C4.1

Anti-C1q antibodies are significantly associated (OR = 3.2, p < 0.01) with LN independent of demographic and other serological risk factors.1,3

SLE patients who are simultaneously anti-dsDNA, low complement, and anti-C1q positive are most strongly associated (OR = 14.9, p < 0.01) with LN2.3

You deserve quality test results you can trust.

Take control over your patient’s lupus with regular monitoring. Uncover what other tests can’t see with AVISE® SLE Monitor, the most advanced autoimmune testing available.

AVISE SLE Monitor is a specialized SLE Disease Monitoring Test Clinically Proven To Correlate With SLE Disease Activity.

The AVISE SLE Monitor test should be considered any time the condition of a SLE patient is being assessed.

Order your AVISE Testing Starter Kit today!

  • This field is for validation purposes and should be left unchanged.